WO2024095137 - PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND PROCESS THEREOF
National phase entry is expected:
Publication Number
WO/2024/095137
Publication Date
10.05.2024
International Application No.
PCT/IB2023/060936
International Filing Date
31.10.2023
Title **
[English]
PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND PROCESS THEREOF
[French]
COMPOSITION PHARMACEUTIQUE D'EMPAGLIFLOZINE ET PROCÉDÉ ASSOCIÉ
Applicants **
MOREPEN LABORATORIES LIMITED
Inventors
CHATURVEDI, Kiran
SAXENA, Arjit
SURI, Sanjay
Priority Data
202211063288
05.11.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1956 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2001 | |
| South Korea | Filing, Examination, Granting | 1805 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,078
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a stable pharmaceutical composition of empagliflozin or its pharmaceutically acceptable salts, solvates thereof along with one or more pharmaceutically acceptable excipients. More specifically, the present invention relates to a process of preparing a stable pharmaceutical composition of empagliflozin.[French]
La présente invention concerne une composition pharmaceutique stable d'empagliflozine ou de ses sels pharmaceutiquement acceptables, des solvates de celle-ci conjointement avec un ou plusieurs excipients pharmaceutiquement acceptables. Plus spécifiquement, la présente invention concerne un procédé de préparation d'une composition pharmaceutique stable d'empagliflozine.